Dibenzyline

Urinary Retention, Dysuria, Pheochromocytoma

Treatment

2 FDA approvals

20 Active Studies for Dibenzyline

What is Dibenzyline

Phenoxybenzamine

The Generic name of this drug

Treatment Summary

An alpha-adrenergic antagonist is a type of drug used to lower high blood pressure and widen the blood vessels to improve blood flow. It works over a long period of time.

Dibenzyline

is the brand name

Dibenzyline Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Dibenzyline

Phenoxybenzamine

1953

8

Approved as Treatment by the FDA

Phenoxybenzamine, also known as Dibenzyline, is approved by the FDA for 2 uses which include Pheochromocytomas and Pheochromocytoma .

Pheochromocytomas

Pheochromocytoma

Effectiveness

How Dibenzyline Affects Patients

Phenoxybenzamine is used to treat high blood pressure and excessive sweating caused by a disease called pheochromocytoma. It works by blocking certain alpha receptors in the body, which relaxes the muscles in the walls of the blood vessels and widens them. This helps to lower blood pressure. If the heart rate is too high, a beta-blocking agent may be used along with Phenoxybenzamine.

How Dibenzyline works in the body

Phenoxybenzamine relaxes muscles and lowers blood pressure by blocking certain receptors in the body. This helps widen the blood vessels, allowing more blood to flow more freely.

When to interrupt dosage

The dosage of Dibenzyline is contingent upon the determined malady, including Dysuria, Pheochromocytomas and Urinary Retention. The measure of dosage is contingent upon the technique of administration referenced in the table below.

Condition

Dosage

Administration

Dysuria

, 10.0 mg

Capsule - Oral, , Oral, Capsule

Urinary Retention

, 10.0 mg

Capsule - Oral, , Oral, Capsule

Pheochromocytoma

, 10.0 mg

Capsule - Oral, , Oral, Capsule

Warnings

Dibenzyline has one contraindication. If you have any of the conditions given in the table below, Dibenzyline should not be utilized.

Dibenzyline Contraindications

Condition

Risk Level

Notes

Hypotension

Do Not Combine

There are 20 known major drug interactions with Dibenzyline.

Common Dibenzyline Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Alfuzosin

Major

Phenoxybenzamine may increase the hypotensive activities of Alfuzosin.

Amifostine

Major

Phenoxybenzamine may increase the hypotensive activities of Amifostine.

Aripiprazole

Major

Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Aripiprazole lauroxil

Major

Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.

Dibenzyline Toxicity & Overdose Risk

Symptoms of an overdose of Atropine may include fainting or dizziness from low blood pressure, a faster than normal heart rate, vomiting, tiredness, and shock. These symptoms are typically caused by blockage of the sympathetic nervous system and epinephrine.

image of a doctor in a lab doing drug, clinical research

Dibenzyline Novel Uses: Which Conditions Have a Clinical Trial Featuring Dibenzyline?

19 active investigations are presently examining the potential of Dibenzyline to mitigate Urinary Retention, Dysuria and Pheochromocytomas.

Condition

Clinical Trials

Trial Phases

Urinary Retention

8 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Dysuria

0 Actively Recruiting

Pheochromocytoma

0 Actively Recruiting

Dibenzyline Reviews: What are patients saying about Dibenzyline?

4

Patient Review

2/21/2012

Dibenzyline for Tumor of Adrenal Gland Causing High Blood Pressure

This medication does help to ease my symptoms, but I have to take a larger dose than recommended for it to be completely effective. The downside to this is that I feel very lightheaded and dizzy.

4

Patient Review

10/8/2007

Dibenzyline for Tumor of Adrenal Gland Causing High Blood Pressure

This medication is helping me to get ready for surgery.

3.7

Patient Review

10/26/2008

Dibenzyline for Tumor of Adrenal Gland Causing High Blood Pressure

I am currently taking this treatment leading up to my surgery on 11/3. I have found it difficult to breathe; the constant stuffed nose is very unpleasant. However, there are some benefits: my blood pressure has lowered and I don't sweat as much anymore.

2.7

Patient Review

2/16/2011

Dibenzyline for Tumor of Adrenal Gland Causing High Blood Pressure

My blood pressure is under control now, but I still have a really bad sweating problem all over my body. I've seen several doctors about this, but no one has been able to help me.

Patient Q&A Section about dibenzyline

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Phenoxybenzamine used for?

"Phenoxybenzamine is used to treat high blood pressure (hypertension) caused by a disease called pheochromocytoma. By blocking the effects of certain chemicals in the body, phenoxybenzamine helps to control blood pressure."

Answered by AI

What class of drug is Dibenzyline?

"Dibenzyline is an Alpha Blocker and Antihypertensive."

Answered by AI

What is Dibenzyline used for?

"This medication is used to treat high blood pressure caused by a certain tumor of the adrenal glands (pheochromocytoma). Phenoxybenzamine belongs to a class of drugs known as alpha blockers. It relaxes and widens blood vessels so that blood can flow more easily."

Answered by AI

Clinical Trials for Dibenzyline

Image of Durham VA Medical Center, Durham, NC in Durham, United States.

Mobile Health App for Urinary Incontinence

Any Age
Female
Durham, NC

Implementing a Mobile Health Application for Women Veterans with Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0 aims to compare implementation approaches while also gathering information on clinical effects of the EBP in its new context and focusing on equitable reach (extent to which the program serves its intended audience). The overall goal is to address a key priority within the implementation science field - identifying and refining metrics for equity and impact. The overall goal is to implement, evaluate, and sustain MyHealtheBladder in 20 VA facilities using a type III effectiveness-implementation hybrid study framework and parallel CRT design.

Waitlist Available
Has No Placebo

Durham VA Medical Center, Durham, NC

Karen Goldstein, MD MSPH

Have you considered Dibenzyline clinical trials?

We made a collection of clinical trials featuring Dibenzyline, we think they might fit your search criteria.
Go to Trials
Image of The University of Chicago in Chicago, United States.

SUPPORT Workbook for Urinary Incontinence

18+
Female
Chicago, IL

The study is designed to address the disparity in available conservative/behavioral treatments for UI/LUTS. The program was developed by experts from urogynecology, psychology, and physical therapy then modified based on focus group feedback from racially minoritized women. The study team created a patient-centered, culturally adapted, self-directed, 8-week, home-based module for women with LUTS/UI. The SUPPORT program combines multiple evidence-based conservative treatments for LUTS/UI including cognitive behavioral therapy, behavioral modifications, and home physical therapy exercise. Progression through the home-based program is supported by research staff. This prospective interventional study aims to evaluate the feasibility and acceptability of the SUPPORT program and its impact on patient-centered treatment outcomes, while enabling comparisons across race and ethnicity. This approach will provide a comprehensive understanding of how to effectively deliver self-management strategies for pelvic floor disorders. At the start of the 8 week SUPPORT course participants will also be given access to a custom programmed GPT trained on the SUPPORT workbook and given instructions on empathetic communication techniques and assisting patients in performing the SUPPORT exercises as outlined in the program. At the end of 8 weeks patients will fill out a survey assessing the frequency of use and interactions with the LLM.

Recruiting
Has No Placebo

The University of Chicago (+1 Sites)

Kimberly Kenton, MD

Image of Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) in Basking Ridge, United States.

Pelvic Floor Exercises for Prostate Cancer

18+
Male
Basking Ridge, NJ

The researchers are doing this study to find out if a PFME program to reduce urinary incontinence after radical prostatectomy is feasible for people with prostate cancer. The researchers will track how many participants join the study, follow the program, and stay in the study. They will also evaluate how people feel about their experience and satisfaction with participating in this program through interviews. They will also measure participants' quality of life by filling out questionnaires, and we will study whether the program shows promise in reducing urinary incontinence. Radical prostatectomy sometimes causes incontinence after the surgery. The researchers think that by teaching PFME and strengthening and improving control of the pelvic floor muscles, PFME training before and after radical prostatectomy may help reduce incontinence and/or reduce how long incontinence lasts.

Recruiting
Has No Placebo

Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) (+6 Sites)

James Eastham, MD

Have you considered Dibenzyline clinical trials?

We made a collection of clinical trials featuring Dibenzyline, we think they might fit your search criteria.
Go to Trials
Image of Clinique des maladies neuromusculaires in Jonquière, Canada.

Pelvic Floor Muscle Training for Myotonic Dystrophy

18+
Female
Jonquière, Canada

Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystem manifestations. DM1 can affect the urinary system through the impact of the pelvic floor muscles (PFM). Urinary incontinence can occur in this situation and is often offset with compensatory measures without restoring the PFM function (e.g. sanitary pads). PFM training have already been shown to be effective in reducing or even eliminating urinary incontinence in the general population. However, no study has been the subject of this modality in people with DM1. Having recently shown that it is possible to gain strength with DM1, a strengthening protocol targeting PFM could prove effective in treating urinary incontinence. The objectives of this study are i) to assess the feasibility and acceptability of PFM training and ii) to investigate the effects of PFM training in women with DM1 with adult phenotype. A quasi-experimental study will be conducted with 12 women having a confirmed diagnosis of DM1 with urinary incontinence. Participants will follow a 12-week PFM training program, comprising weekly sessions with an experienced physiotherapist as well as a home exercise program. Outcomes measures will be assessed at baseline and at post-treatment and will include: feasibility and acceptability variables, frequency of urinary incontinence, urogynecological symptoms and their impact on quality of life, morphometry and function of PFM, and the perceived improvement following the treatments. This study has the potential to improve the management of urinary incontinence and support the implementation of pelvic floor rehabilitation services in this population.

Recruiting
Has No Placebo

Clinique des maladies neuromusculaires

Have you considered Dibenzyline clinical trials?

We made a collection of clinical trials featuring Dibenzyline, we think they might fit your search criteria.
Go to Trials